mmkkfdm3355 mmkkfdm3355 28-02-2024 Medicine contestada What mechanisms of action and/or drug classes are currently available or in development for the treatment of patients with myelofibrosis? a) JAK (Janus kinase) inhibitors b) Monoclonal antibodies c) Tyrosine kinase inhibitors d) Antimetabolites